Samyang Biopharmaceuticals win patent trial of ‘Palseron’ against global pharmas

Published: 2018-01-05 16:09:32

Updated: 2018-01-05 16:09:32

Samyang Biopharmaceuticals(CEO Tae-Woong Um) announced on the 3^rd the company has won the 1^st trial of patent infringement related to ‘Palseron Inj(generic name: palonosetron hydrochloride)’ against Helsinn Healthcare SA., a global Swiss pharmaceutical company.

Last 21 December, Seoul Central District Court Civil Affairs 63 ruled dismissals on all the charges that the plaintiff made at the inj...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.